SLC49A4

Summary

SLC49A4 (solute carrier family 49 member 4, HGNC:16628) is a protein-coding gene on chromosome 3q21.1, encoding Solute carrier family 49 member 4 (Q96SL1). Mediates H(+)-dependent pyridoxine transport.

This gene encodes a membrane-bound protein from the major facilitator superfamily of transporters. Disruption of this gene by translocation has been associated with haplo-insufficiency and renal cell carcinomas. Alternatively spliced transcript variants have been described, but their biological validity has not yet been determined.

Source: NCBI Gene 84925 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 65 total
• MANE Select transcript: NM_032839

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16628
Approved symbol	SLC49A4
Name	solute carrier family 49 member 4
Location	3q21.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ14784, RCC4
Ensembl gene	ENSG00000138463
Ensembl biotype	protein_coding
OMIM	602773
Entrez	84925

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 5 protein_coding, 1 nonsense_mediated_decay

ENST00000261038, ENST00000477647, ENST00000864462, ENST00000864463, ENST00000935842, ENST00000960629

RefSeq mRNA: 1 — MANE Select: NM_032839 NM_032839

CCDS: CCDS3018

Canonical transcript exons

ENST00000261038 — 9 exons

Exon	Start	End
ENSE00001050012	122806857	122806950
ENSE00001154533	122879263	122881139
ENSE00001812543	122795069	122795535
ENSE00003467829	122856307	122856374
ENSE00003482223	122860075	122860202
ENSE00003504315	122826800	122827065
ENSE00003557153	122845763	122845871
ENSE00003647797	122872415	122872597
ENSE00003657400	122833317	122833446

Expression profiles

Bgee: expression breadth ubiquitous, 253 present calls, max score 98.39.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 14.9569 / max 402.5452, expressed in 1775 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
38269	13.4832	1774
38266	0.6479	164
38265	0.4934	148
38270	0.3324	173

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	98.39	gold quality
esophagus squamous epithelium	UBERON:0006920	95.64	gold quality
oocyte	CL:0000023	95.45	gold quality
upper arm skin	UBERON:0004263	94.91	gold quality
placenta	UBERON:0001987	93.87	gold quality
decidua	UBERON:0002450	93.51	gold quality
tibialis anterior	UBERON:0001385	92.77	gold quality
cardiac muscle of right atrium	UBERON:0003379	92.64	gold quality
deltoid	UBERON:0001476	92.41	gold quality
epithelial cell of pancreas	CL:0000083	92.39	gold quality
left ventricle myocardium	UBERON:0006566	91.41	gold quality
gingival epithelium	UBERON:0001949	91.36	gold quality
palpebral conjunctiva	UBERON:0001812	91.30	gold quality
quadriceps femoris	UBERON:0001377	91.28	gold quality
gingiva	UBERON:0001828	91.28	gold quality
vastus lateralis	UBERON:0001379	91.24	gold quality
kidney epithelium	UBERON:0004819	91.09	gold quality
biceps brachii	UBERON:0001507	90.99	gold quality
oral cavity	UBERON:0000167	90.86	gold quality
nasal cavity epithelium	UBERON:0005384	90.50	gold quality
skeletal muscle tissue	UBERON:0001134	90.15	gold quality
penis	UBERON:0000989	89.90	gold quality
epithelium of nasopharynx	UBERON:0001951	89.52	gold quality
mucosa of sigmoid colon	UBERON:0004993	89.33	gold quality
muscle tissue	UBERON:0002385	89.18	gold quality
gastrocnemius	UBERON:0001388	89.14	gold quality
ileal mucosa	UBERON:0000331	88.93	gold quality
muscle of leg	UBERON:0001383	88.82	gold quality
pancreatic ductal cell	CL:0002079	88.70	gold quality
colonic mucosa	UBERON:0000317	88.58	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.07

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

119 targeting SLC49A4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-196A-5P	100.00	68.16	684
HSA-MIR-196B-5P	100.00	68.16	681
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-512-3P	99.97	67.35	1049
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-338-5P	99.92	72.34	2951
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-6499-3P	99.90	66.38	1212
HSA-MIR-3686	99.90	70.53	2432

Literature-anchored findings (GeneRIF, showing 3)

• Gene disruption may result in haplo-insufficiency and, through this mechanism, in the onset of tumor growth. (PMID:11912179)
• Data strongly support the idea that DIRC2 is an electrogenic lysosomal metabolite transporter which is subjected to and presumably modulated by limited proteolytic processing. (PMID:21692750)
• Disrupted in renal carcinoma 2 (DIRC2/SLC49A4) is an H[+]-driven lysosomal pyridoxine exporter. (PMID:36456177)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	slc49a4	ENSDARG00000009783
mus_musculus	Slc49a4	ENSMUSG00000022848
rattus_norvegicus	Slc49a4	ENSRNOG00000002240

Paralogs (4): FLVCR2 (ENSG00000119686), FLVCR1 (ENSG00000162769), SLC49A3 (ENSG00000169026), CFAP276 (ENSG00000179902)

Protein

Protein identifiers

Solute carrier family 49 member 4 — Q96SL1 (reviewed: Q96SL1)

Alternative names: Disrupted in renal cancer protein 2, Disrupted in renal carcinoma protein 2

All UniProt accessions (2): Q96SL1, Q05BS2

UniProt curated annotations — full annotation on UniProt →

Function. Mediates H(+)-dependent pyridoxine transport.

Subcellular location. Lysosome membrane.

Tissue specificity. Ubiquitous. Expressed in proximal tubular cells of the kidney. Highly expressed in the placenta, brain and heart.

Post-translational modifications. Cleaved in lysosomes by cathepsin L between Leu-214 and Ala-261, generating a N-glycosylated N-terminal and a non-glycosylated C-terminal fragment.

Disease relevance. A chromosomal aberration involving DIRC2 has been found in a family with renal carcinoma. Translocation t(2;3)(q35;q21).

Similarity. Belongs to the major facilitator superfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q96SL1-1	1	yes
Q96SL1-2	2

RefSeq proteins (1): NP_116228* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR011701	MFS	Family
IPR036259	MFS_trans_sf	Homologous_superfamily
IPR049604	SLC49A4-like	Family
IPR049680	FLVCR1-2_SLC49-like	Family

Pfam: PF07690

Catalyzed reactions (Rhea), 1 shown:

• pyridoxine(out) + n H(+)(out) = pyridoxine(in) + n H(+)(in) (RHEA:76203)

UniProt features (31 total): topological domain 13, transmembrane region 12, splice variant 2, chain 1, short sequence motif 1, glycosylation site 1, mutagenesis site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96SL1-F1	84.53	0.54

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (1): 209

Mutagenesis-validated functional residues (1):

Position	Phenotype
14–15	abolishes lysosomal localization.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 197 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_DN, TAATAAT_MIR126, GOCC_VACUOLAR_MEMBRANE, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, GOBP_ORGANIC_HYDROXY_COMPOUND_TRANSPORT, CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP, MYCMAX_01, USF_01, GOBP_VITAMIN_TRANSPORT, ATF4_Q2, CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_DN, chr3q21, WESTON_VEGFA_TARGETS_6HR, WESTON_VEGFA_TARGETS_12HR, WESTON_VEGFA_TARGETS

GO Biological Process (2): pyridoxine transport (GO:0031923), transmembrane transport (GO:0055085)

GO Molecular Function (1): transmembrane transporter activity (GO:0022857)

GO Cellular Component (3): lysosomal membrane (GO:0005765), membrane (GO:0016020), lysosome (GO:0005764)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
organic hydroxy compound transport	1
vitamin B6 transport	1
transport	1
cellular process	1
transporter activity	1
transmembrane transport	1
lysosome	1
lytic vacuole membrane	1
cellular anatomical structure	1
lytic vacuole	1

Protein interactions and networks

STRING

492 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC49A4	VHL	P40337	817
SLC49A4	EPAS1	Q99814	772
SLC49A4	HSPBAP1	Q96EW2	732
SLC49A4	DIRC1	Q969H9	697
SLC49A4	CA9	Q16790	694
SLC49A4	EGLN3	Q9H6Z9	649
SLC49A4	HIF1A	Q16665	621
SLC49A4	CUL2	Q13617	593
SLC49A4	EGLN1	Q9GZT9	582
SLC49A4	EGLN2	Q96KS0	572
SLC49A4	RNF139	Q8WU17	563
SLC49A4	HIF1AN	Q9NWT6	560
SLC49A4	ELOB	Q15370	549
SLC49A4	LRIG1	Q96JA1	540
SLC49A4	ELOC	Q15369	523

IntAct

8 interactions, top by confidence:

A	B	Type	Score
	ESYT2	psi-mi:“MI:0914”(association)	0.350
E5	ESYT2	psi-mi:“MI:0914”(association)	0.350
Npc1	ESYT2	psi-mi:“MI:0914”(association)	0.350
BSCL2	TMEM223	psi-mi:“MI:0914”(association)	0.350
SLC22A4	RTL8C	psi-mi:“MI:0914”(association)	0.350
BSCL2	QSOX1	psi-mi:“MI:0914”(association)	0.350
SLC49A4	AP3B1	psi-mi:“MI:0914”(association)	0.350

BioGRID (48): DIRC2 (Affinity Capture-MS), DIRC2 (Affinity Capture-MS), DIRC2 (Affinity Capture-MS), DIRC2 (Affinity Capture-MS), DIRC2 (Affinity Capture-MS), DIRC2 (Affinity Capture-RNA), DIRC2 (Affinity Capture-MS), ABCA3 (Affinity Capture-MS), ACAD10 (Affinity Capture-MS), GPR64 (Affinity Capture-MS), AMFR (Affinity Capture-MS), ANKRD13D (Affinity Capture-MS), ANKS6 (Affinity Capture-MS), AP3B1 (Affinity Capture-MS), AP3S1 (Affinity Capture-MS)

ESM2 similar proteins: A0A3Q2HW92, A6NDV4, A6NFX1, A6QLK4, B1AWJ5, F1NCD6, F1NJ67, F1PZV2, O35308, O35595, O70461, O95907, Q08DX7, Q0IHM1, Q0P5C0, Q0P5M9, Q13286, Q14728, Q29611, Q2YDU8, Q3T9M1, Q3U481, Q501I9, Q5R8G5, Q5R9A1, Q5U419, Q60HH0, Q61124, Q66H95, Q6NUT3, Q6UXD7, Q6ZMD2, Q7RTT9, Q8BFQ6, Q8CE47, Q8NA29, Q8R0G7, Q8R139, Q8TB61, Q8VCW4

Diamond homologs: A0A0R4ILB2, A0A8M9Q308, B2RXV4, O01735, P60815, Q28FF3, Q501I9, Q66H95, Q6GNV7, Q8BFQ6, Q91X85, Q96SL1, Q9ES43, Q9N1F2, Q9UPI3, Q9Y5Y0, Q6UXD7, Q8CE47

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

65 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	47
Likely benign	1
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1964 predictions. Top by Δscore:

Variant	Effect	Δscore
3:122806852:TTTA:T	acceptor_loss	1.0000
3:122806853:TTAG:T	acceptor_loss	1.0000
3:122806854:TA:T	acceptor_loss	1.0000
3:122806855:A:AG	acceptor_gain	1.0000
3:122806856:G:GG	acceptor_gain	1.0000
3:122806856:G:GT	acceptor_loss	1.0000
3:122806947:GAAG:G	donor_gain	1.0000
3:122845867:GCCAA:G	donor_gain	1.0000
3:122845872:G:GG	donor_gain	1.0000
3:122856304:CA:C	acceptor_loss	1.0000
3:122856305:A:T	acceptor_loss	1.0000
3:122856306:GGTA:G	acceptor_gain	1.0000
3:122856374:GGT:G	donor_loss	1.0000
3:122856375:GTGAG:G	donor_loss	1.0000
3:122856376:T:A	donor_loss	1.0000
3:122860073:A:AG	acceptor_gain	1.0000
3:122860073:AG:A	acceptor_gain	1.0000
3:122860074:G:A	acceptor_gain	1.0000
3:122860074:G:GA	acceptor_loss	1.0000
3:122860074:G:GT	acceptor_gain	1.0000
3:122860074:GGT:G	acceptor_gain	1.0000
3:122860128:C:CA	acceptor_gain	1.0000
3:122860129:G:A	acceptor_gain	1.0000
3:122860201:AGGTG:A	donor_loss	1.0000
3:122860202:GGTGA:G	donor_loss	1.0000
3:122860203:G:GA	donor_loss	1.0000
3:122860204:T:G	donor_loss	1.0000
3:122872550:A:AG	donor_gain	1.0000
3:122795531:GAGAG:G	donor_gain	0.9900
3:122795533:GAG:G	donor_gain	0.9900

AlphaMissense

3046 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:122826882:T:C	F174L	0.999
3:122826883:T:C	F174S	0.999
3:122826884:T:A	F174L	0.999
3:122826884:T:G	F174L	0.999
3:122795406:T:A	W72R	0.998
3:122795406:T:C	W72R	0.998
3:122826871:C:T	S170F	0.998
3:122826879:T:A	W173R	0.998
3:122826879:T:C	W173R	0.998
3:122826883:T:G	F174C	0.998
3:122826907:C:A	A182D	0.998
3:122826871:C:A	S170Y	0.997
3:122826881:G:C	W173C	0.997
3:122826881:G:T	W173C	0.997
3:122826882:T:A	F174I	0.997
3:122826882:T:G	F174V	0.996
3:122826913:C:A	A184D	0.996
3:122826954:T:C	F198L	0.996
3:122826956:T:A	F198L	0.996
3:122826956:T:G	F198L	0.996
3:122845824:T:A	W299R	0.996
3:122845824:T:C	W299R	0.996
3:122856358:G:A	G332R	0.996
3:122856358:G:C	G332R	0.996
3:122872459:A:C	S395R	0.996
3:122872461:C:A	S395R	0.996
3:122872461:C:G	S395R	0.996
3:122872480:G:A	E402K	0.996
3:122872484:T:C	L403P	0.996
3:122872492:G:A	E406K	0.996

dbSNP variants (sampled 300 via entrez): RS1000019190 (3:122843481 A>G), RS1000040799 (3:122816352 C>A), RS1000063737 (3:122841550 G>A,C), RS1000065627 (3:122868774 T>C), RS1000103834 (3:122815562 C>T), RS1000195499 (3:122839585 A>G), RS1000236767 (3:122852867 T>A), RS1000258493 (3:122860749 T>C), RS1000283272 (3:122861101 A>G), RS1000300074 (3:122875092 G>A), RS1000307135 (3:122815923 G>A), RS1000327664 (3:122846945 C>G), RS1000332061 (3:122875410 G>C), RS1000400822 (3:122820092 A>G), RS1000421315 (3:122868087 C>T)

Disease associations

OMIM: gene MIM:602773 | disease phenotypes: MIM:167000

GenCC curated gene-disease

Mondo (1): ovarian cancer (MONDO:0008170)

Orphanet (1): Rare ovarian cancer (Orphanet:213500)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST006988_59	Blond vs. brown/black hair color	3.000000e-27

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0003924	hair color

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D010051	Ovarian Neoplasms	C04.588.322.455; C12.050.351.500.056.630.705; C12.050.351.937.418.685; C12.100.250.056.630.705; C12.900.418.685; C19.344.410; C19.391.630.705

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — SLC49 family of FLVCR-related heme transporters

CTD chemical–gene interactions

23 total (human), top 23 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, affects cotreatment, increases expression	8
sodium arsenite	increases expression	2
Tobacco Smoke Pollution	decreases expression, increases expression	2
FR900359	decreases phosphorylation	1
bisphenol A	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
Norethindrone Acetate	affects cotreatment, increases expression	1
Acetaminophen	increases expression	1
Arsenic	increases methylation	1
Benzene	increases expression	1
Carbamazepine	affects expression	1
Doxorubicin	decreases expression	1
Estradiol	affects cotreatment, increases expression	1
Ethyl Methanesulfonate	increases expression	1
Formaldehyde	increases expression	1
Methyl Methanesulfonate	increases expression	1
Mustard Gas	increases expression	1
Quercetin	decreases expression	1
Tretinoin	increases expression	1
Urethane	increases expression	1
Aflatoxin B1	decreases methylation	1
Copper Sulfate	decreases expression	1

Cellosaurus cell lines

5 cell lines: 5 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D4FX	HCT116-DIRC2-KO-c5	Cancer cell line	Male
CVCL_D4FY	HCT116-DIRC2-KO-c7	Cancer cell line	Male
CVCL_E0P0	Ubigene HeLa SLC49A4 KO	Cancer cell line	Female
CVCL_SK87	HAP1 DIRC2 (-) 1	Cancer cell line	Male
CVCL_SK88	HAP1 DIRC2 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00190697	PHASE4	COMPLETED	A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment
NCT00277160	PHASE4	COMPLETED	A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
NCT00727961	PHASE4	COMPLETED	A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)
NCT00740116	PHASE4	COMPLETED	Tranexamic Acid in Surgery of Advanced Ovarian Cancer
NCT00817479	PHASE4	COMPLETED	Tumor Gene Expression in Women With Ovarian Cancer
NCT01432015	PHASE4	COMPLETED	Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
NCT01706120	PHASE4	UNKNOWN	Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab
NCT01932125	PHASE4	COMPLETED	An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
NCT01953107	PHASE4	COMPLETED	Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates.
NCT02035345	PHASE4	TERMINATED	Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment
NCT02243059	PHASE4	WITHDRAWN	Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer
NCT03164980	PHASE4	TERMINATED	QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer
NCT03384511	PHASE4	COMPLETED	The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
NCT03543462	PHASE4	COMPLETED	Diaphragmatic Resection And Gynecological Ovarian Neoplasm
NCT03752216	PHASE4	COMPLETED	NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.
NCT03858166	PHASE4	TERMINATED	Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer
NCT04024254	PHASE4	COMPLETED	A Study of Serum Folate Levels in Patients Treated With Olaparib
NCT04330040	PHASE4	COMPLETED	Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer
NCT04352439	PHASE4	COMPLETED	Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy
NCT05187208	PHASE4	UNKNOWN	PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer
NCT05606692	PHASE4	RECRUITING	Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics)
NCT05926336	PHASE4	RECRUITING	The Effects of Using Different Anesthetics on the Prognosis of Primary Tumors and Its Mechanism of Action
NCT06412120	PHASE4	RECRUITING	Study Evaluating Safety, Tolerability, and Metabolism of Niraparib
NCT06871787	PHASE4	NOT_YET_RECRUITING	Near-Infrared Fluorescence Imaging With Indocyanine Green to Evaluate Bowel Anastomoses in Gynecologic Oncology Surgery
NCT06887933	PHASE4	NOT_YET_RECRUITING	A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer
NCT07469202	PHASE4	NOT_YET_RECRUITING	CYTALUX Dose Extension Study
NCT00001806	PHASE3	COMPLETED	Methods in Education for Breast Cancer Genetics
NCT00002477	PHASE3	UNKNOWN	Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer
NCT00002568	PHASE3	COMPLETED	Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer
NCT00002641	PHASE3	COMPLETED	Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
NCT00002717	PHASE3	COMPLETED	Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer
NCT00002764	PHASE3	COMPLETED	Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma
NCT00002819	PHASE3	TERMINATED	Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer
NCT00002894	PHASE3	COMPLETED	Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer
NCT00002895	PHASE3	COMPLETED	Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer
NCT00003120	PHASE3	COMPLETED	S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
NCT00003214	PHASE3	COMPLETED	Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer
NCT00003322	PHASE3	COMPLETED	Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer
NCT00003636	PHASE3	COMPLETED	Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer
NCT00003644	PHASE3	COMPLETED	Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer